Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...

FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

And Arcutis Biotherapeutics announced approval of roflumilast (Zoryve) topical foam 0.3% for plaque psoriasis of the scalp ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

Biotechnology company Optigo Biotherapeutics received the People’s Choice Award at the 2025 Eyecelerator meeting for the ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Results of a phase IIb trial comparing UBX1325 to anti-VEGF therapy are expected later this year. A single intravitreal injection of UBX1325 (foselutoclax), a novel senolytic small molecule ...

Researcher works with universities of California-Davis, Illinois, Wisconsin and others to engineer and test a novel microsphere-hydrogel delivery for medicine, requiring fewer injections, to treat a c ...